Result of Annual General Meeting

Hemogenyx Pharmaceuticals PLC

27 June 2024

 

27 June 2024

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

Result of Annual General Meeting

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
1. To receive and adopt the Company's annual accounts for the year ended 31 December 2023.	172,981,350	99.89	189,346	0.11	173,170,696	12.91	804,255
2. To approve the Directors' Remuneration Report which is set out in the 2023 Annual Report and Accounts.	155,914,909	90.14	17,056,623	9.86	172,971,532	12.89	1,003,419
3. To re-appoint Sir Marc Feldmann as a Director of the Company.	168,819,296	97.51	4,316,573	2.49	173,135,869	12.90	839,082
4. To re-appoint PKF Littlejohn LLP as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	156,805,252	99.10	1,429,684	0.90	158,234,936	11.79	15,740,015
5.​ To authorise the Audit Committee to agree  the auditor's remuneration​.	157,329,629	90.99	15,576,903	9.01	172,906,532	12.89	1,068,419
6. To authorise the Directors to allot shares pursuant to section 551 of the Companies Act 2006.​	153,328,931	88.71	19,513,766	11.29	172,842,697	12.88	1,132,254
Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
7. To disapply pre-emption rights under section 570 of the Companies Act 2006.	152,661,902	88.30	20,235,808	11.70	172,897,710	12.89	1,077,241
8. To approve for calling of general meetings (other than AGMs) on 14 days' notice.	172,081,747	99.38	1,080,015	0.62	173,161,762	12.91	813,189

(1)        The Company's issued share capital ("ISC") on 25 June 2024, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,341,815,988 ordinary shares.

(2)        A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	[e-mail]
Peter Redmond, Director	[e-mail]
SP Angel Corporate Finance LLP	Tel: [phone]
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: [phone]
Lucy Williams, Duncan Vasey, Charles Goodfellow

 

END